Glucocorticoid-induced diabetes mellitus: Prevalence and risk factors in primary renal diseases

Nephron - Clinical Practice

Volumn 105, Issue 2, 2007, Pages

  Uzu, T ^a   Harada, T ^b   Sakaguchi, M ^a   Kanasaki, M ^a   Isshiki, K ^a   Araki, S ^a   Sugiomoto, T ^a   Koya, D ^c   Haneda, M ^d   Kashiwagi, A ^a   Yamauchi, A ^b  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b OSAKA ROSAI HOSPITAL   (Japan)

^c KANAZAWA MEDICAL UNIVERSITY   (Japan)

^d ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Diabetes mellitus; Glucocorticoid induced DM, risk factors; Kidney disease; Steroids

Indexed keywords

METHYLPREDNISOLONE; PREDNISOLONE;

ADULT; AGE; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONFIDENCE INTERVAL; DIABETES MELLITUS; FEMALE; GLOMERULONEPHRITIS; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; HUMAN; HYPERGLYCEMIA; KIDNEY DISEASE; MALE; MEMBRANOUS GLOMERULONEPHRITIS; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TIME SERIES ANALYSIS;

ADULT; AGE FACTORS; BLOOD GLUCOSE; BODY MASS INDEX; CIRCADIAN RHYTHM; DIABETES MELLITUS; FEMALE; GLUCOCORTICOIDS; GLYCOSURIA; HUMANS; HYPERGLYCEMIA; KIDNEY DISEASES; MALE; METHYLPREDNISOLONE; MIDDLE AGED; POSTPRANDIAL PERIOD; PREDNISOLONE; PREVALENCE; RISK FACTORS;

EID: 33846349338     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000097598     Document Type: Article

References (13)

1. Hirsch IB, Paauw DS: Diabetes management in special situations. Endocrinol Metab Clin North Am 1997;26:631-645.
2. Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B, Kohler JA, Furst DE: Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994;96:115-123.
3. Panthakalam S, Bhatnagar D, Klimiuk P: The prevalence and management of hyperglycaemia in patients with rheumatoid arthritis on corticosteroid therapy. Scott Med J 2004;49:139-141.
4. Lentine KL, Brennan DC, Schnitzler MA: Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol 2005;16:496-506.
5. Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J: Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 1994;154:97-101.
6. Schiel R, Heinrich S, Steiner T, Ott U, Stein G: Post-transplant diabetes mellitus: risk factors, frequency of transplant rejections, and long-term prognosis. Clin Exp Nephrol 2005;9:164-169.
7. Hoogwerf B, Danese RD: Drug selection and the management of corticosteroid-related diabetes mellitus. Rheum Dis Clin North Am 1999;25:489-505.
8. Benhamou PY, Penforinis A: Natural history, prognosis, and management of transplantation-induced diabetes mellitus. Diabetes Metab (Paris) 2002;28:166-175.
9. Hjelmesaeth J, Hagen M, Hartmann A, Midtvedt K, Egeland T, Jenssen T: The impact of impaired insulin release and insulin resistance on glucose intolerance after renal transplantation. Clin Transplant 2002;16:389-396.
10. Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, Magnuson MA, Redha R, Zhang Y, Breyer MD: Thiazolidinediones expand body fluid volume through PPAR-γ stimulation of ENaC-mediated renal salt absorption. Nat Med 2005;11:861-866.
11. Fuhlendorff J, Rorsman P, Kofod H, Brand CL, Rolin B, MacKay P, Shymko R, Carr RD: Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 1998;47:345-351.
12. Hollander PA, Schwartz SL, Gatlin MR, Haas SJ, Zheng H, Foley JE, Dunning BE: Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care 2001;24:983-988.
13. Andrade IS, Monsalve RMC, Martinez De Hurtado E, Chacin LF, Caminos QR, Yupanqui H, Lopez G, De La Torre W: Evaluation of the effects of nateglinide on postprandial glycemia in patients with type 2 diabetes mellitus: a multicenter, multinational, nonrandomized, non-controlled Latin American study. Pharmacology 2003;68:89-95.